Trial · NCT04935931

Naltrexone Neuroimaging

NCT04935931, Early phase 1, Completed, Children's Mercy Hospital Kansas City; results first posted 2023-08-21

3 sourcestrials-2026-11-12-0.4.0

Cite this record

ConductScience Library. Naltrexone Neuroimaging. Trials, record NCT04935931. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04935931

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Naltrexone Neuroimaging
NCT number: NCT04935931
Status: Completed
Phases: Early phase 1
Enrollment: 13 participants, actual
Lead sponsor: Children's Mercy Hospital Kansas City
Conditions: Eating Disorders, Binge Eating, Purging (Eating Disorders)
Interventions: Naltrexone
First posted: 2021-06-23
Last updated: 2023-10-12
Results first posted: 2023-08-21

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in % Blood Oxygenation Level Dependent Change (%BOLD) in the Nucleus Accumbens	2 hours post-naltrexone vs baseline	Change in %BOLD following single dose naltrexone (post-pre) within individuals during passive food view task in the nucleus accumbens
Primary	Change in % Blood Oxygenation Level Dependent Change (%BOLD) in the Dorsal Anterior Cingulate Cortex	2 hours post-naltrexone vs baseline	Change in %BOLD following single dose naltrexone (post-pre) within individuals during monetary incentive delay in dorsal anterior cingulate cortex
Secondary	Exposure	2 hours post-naltrexone	Maximum plasma concentration of naltrexone at 2 hours post-single dose

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in % Blood Oxygenation Level Dependent Change (%BOLD) in the Nucleus Accumbens	2 hours post-naltrexone vs baseline		%BOLD signal change	MEAN
PRIMARY	Change in % Blood Oxygenation Level Dependent Change (%BOLD) in the Dorsal Anterior Cingulate Cortex	2 hours post-naltrexone vs baseline		%BOLD signal change	MEAN
SECONDARY	Exposure	2 hours post-naltrexone	plasma concentration	nanomolar	MEAN

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change in % Blood Oxygenation Level Dependent Change (%BOLD) in the Nucleus Accumbens	Single Pre/Post Design	-0.08	Standard Deviation 0.03	%BOLD signal change
Change in % Blood Oxygenation Level Dependent Change (%BOLD) in the Dorsal Anterior Cingulate Cortex	Single Pre/Post Design	0.06	Standard Deviation 0.03	%BOLD signal change
Exposure	Single Pre/Post Design	44.1	Standard Deviation 22.7	nanomolar

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Single Pre/Post Design	13
Overall Study	COMPLETED	Single Pre/Post Design	12
Overall Study	NOT COMPLETED	Single Pre/Post Design	1

Source ClinicalTrials.gov

Adverse events1

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Claustrophobia	Nervous system disorders	Single Pre/Post Design	1	13	1

Source ClinicalTrials.gov

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Single Pre/Post Design	0	13
Total, other adverse events	Single Pre/Post Design	1	13
Total, serious adverse events	Single Pre/Post Design	0	13

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
37492067	DERIVED

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
UL1TR002366	Frontiers Clinical and Translational Science Institute at the University of Kansas	CASTRO, MARIO; LEEDER, JAMES STEVEN	UNIVERSITY OF KANSAS MEDICAL CENTER	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	2017 to 2025

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests1

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as
Monetary Incentive Delay	Primary outcome

Source ConductCognition

Source

Release: trials-2026-11-12-0.4.0
Release manifest SHA-256: 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
Registry capture: 2026-11-12
Results copy, AACT: 2026-03-23
NIH clinical studies file: 2026-11-13

Source ClinicalTrials.gov

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04935931

GET https://conductscience.org/api/trials/v1/NCT04935931/registered

API reference For AI assistants